205 related articles for article (PubMed ID: 19520592)
1. Constitutive increase in active GLP-1 levels by the DPP4 inhibitor ASP4000 on a new meal tolerance test in Zucker fatty rats.
Tanaka-Amino K; Hatakeyama Y; Takakura S; Mutoh S
Pharmacol Res; 2009 Oct; 60(4):264-9. PubMed ID: 19520592
[TBL] [Abstract][Full Text] [Related]
2. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
[TBL] [Abstract][Full Text] [Related]
3. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
[TBL] [Abstract][Full Text] [Related]
4. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
6. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
7. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
8. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
9. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
10. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
11. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
[TBL] [Abstract][Full Text] [Related]
13. [Modulation of the incretin effect in the treatment of diabetes].
Vidal J
Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
Jain MR; Joharapurkar AA; Bahekar RH; Patel H; Jadav P; Kshirsagar SG; Patel VJ; Patel KN; Ramanathan VK; Patel PR; Desai RC
J Diabetes; 2015 Sep; 7(5):708-17. PubMed ID: 25327540
[TBL] [Abstract][Full Text] [Related]
15. Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Hikida K; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Minami M; Shiotani M
J Pharmacol Sci; 2016 Dec; 132(4):255-261. PubMed ID: 27889414
[TBL] [Abstract][Full Text] [Related]
16. The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats.
Mochida T; Hira T; Hara H
Endocrinology; 2010 Jul; 151(7):3095-104. PubMed ID: 20410194
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Reimer RA; Grover GJ; Koetzner L; Gahler RJ; Juneja P; Lyon MR; Wood S
J Nutr; 2012 Oct; 142(10):1812-20. PubMed ID: 22915295
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
